Anzeige
Mehr »
Login
Mittwoch, 08.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Starke Übernahme: Dieses Börsen-Juwel könnte vor einem weiteren gewaltigen Kurssprung stehen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
14 Leser
Artikel bewerten:
(0)

FemOne Announces First Quarter 2006 Earnings Results: Increased Gross Profits by 62%; Increased Sales by 54%


CARLSBAD, Calif., May 22 /PRNewswire-FirstCall/ -- FemOne, Inc. (BULLETIN BOARD: FEMO) , a publicly held Nevada corporation (the "Company"), reported consolidated net sales for the quarter ended March 31, 2006 of $2,695,730 an increase of 54% from the prior year. Sales from the Company's BIOPRO Technology division represented 86% of consolidated revenues for 2006.

The gross profits in 2006 increased to $2,111,390, an increase of 62% over gross profits of $1,306,320 in 2005.

Consolidated net loss from operations for the three months ended March 31, 2006 increased to $539,811, less than 1% over $537,571 in 2005.

Consolidated net loss attributable to common stockholders for the three months ended March 31, 2006 was $1,930,251 or $0.02 per share, compared to net loss of $1,288,246 or $0.04 per share a year ago. Included in the consolidated net loss attributable to common stockholders for the three months ended March 31, 2006 are net non-cash expenses of approximately $1.4 Million from the increase in the valuation of derivative liabilities at March 31, 2006, partially offset by gains recorded in the quarter.


Operating expenses for the three months ended March 31, 2006 were $2,651,201 compared to $1,843,890 for the three months ended March 31, 2005. The increase in operating expenses is due to increased sales commission expense on increased sales, as well as increased sales and marketing expenses due to efforts to promote BIOPRO Technology and expand international operations.

Included in the Company's consolidated results for 2006 are revenues and expenses from its three controlled subsidiaries, BIOPRO Australasia Pty., Ltd, operating the Company's Direct Sales division in Australia and New Zealand, BIOPRO Asia, Inc., operating the Company's Direct Sales division in the Philippines, and SRA Marketing, Inc., its subsidiary for the Direct Response Shopping Network. During the three months ended March 31, 2006, 9% of total revenues came from BIOPRO Australia, 1% from BIOPRO Asia and 9% from SRA Marketing.

Commenting on the Q1 2006 results, Ray W. Grimm, FemOne's chief executive officer states: "We are very pleased with having increased our revenues in the first quarter of 2006 by 54% over the first quarter in 2005. We are also showing our continued momentum to grow revenues quarterly by increasing our revenues by over 20% from the fourth quarter of 2005." "Our consolidated net loss, before the non-cash effects of the accounting treatment of our convertible financings, is continuing to decrease and is approximately 20% less than our net loss from operations for the fourth quarter of 2005, proving our ability to not only grow our sales, but reaching our goal of profitability in the near future."

The information contained in this press release should be read in connection with the Company's Quarterly Report on Form 10-QSB for the period ended March 31, 2006 and its Annual Report on Form 10-KSB for the year ended December 31, 2005. The Report from the Company's Independent Registered Public Accounting Firm contained in the Company's Annual Report on Form 10-KSB includes an explanatory paragraph as to the Company's ability to continue as a going concern and other information necessary for an understanding of the Company.

About FemOne, Inc.

FemOne, Inc. (BULLETIN BOARD: FEMO) , based in Carlsbad, California is a sales and marketing company with distribution in the United States, Canada, Australia, New Zealand, the Philippines and South Africa. More information about FemOne and its products can be found on the company's web sites at http://www.femone.com/ or http://www.bioprotechnology.com/, by e-mail at FEMOIR@femone.com or by calling FemOne Inc. at (760) 448-2498.

Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward- looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward- looking statement.

These forward looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievement expressed or implied by such forward looking statements. In some cases, you can identify forward looking statements by terminology such as "may," "will," "should," "could," "intend," "expects," "plan," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements.

FemOne, Inc. Consolidated Statements of Operations For the Three Months ended March 31, 2006 and 2005 (Unaudited) Three Months Ended March 31, 2006 2005 REVENUES Product sales $2,695,730 $1,752,627 Cost of sales 584,340 446,308 GROSS PROFIT 2,111,390 1,306,319 EXPENSES Sales commissions 1,061,636 744,285 Order fulfillment costs 255,615 137,757 Sales and marketing 725,226 531,033 General and administrative 608,724 430,815 Total operating expenses 2,651,201 1,843,890 NET LOSS FROM OPERATIONS (539,811) (537,571) OTHER INCOME (EXPENSE) Amortization of debt discount (479,303) (564,374) Loss on warrant derivative liability (1,859,201) -- Gain on extinguishment of debt 1,101,070 -- Interest and finance charges (145,433) (148,877) Other income (expense) 1,645 871 Total other income (expense) (1,381,222) (712,380) LOSS BEFORE MINORITY INTEREST AND INCOME TAX EXPENSE (1,921,033) (1,249,951) MINORITY INTEREST IN SUBSIDIARIES (3,218) (38,294) INCOME TAX EXPENSE (6,000) -- NET LOSS $(1,930,251) $(1,288,245) NET LOSS PER COMMON SHARE - Basic and Diluted $(0.02) $(0.04) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and Diluted 118,796,973 36,501,733 FemOne, Inc. Consolidated Balance Sheets (Unaudited) March 31, December 31, 2006 2005 ASSETS Current assets Cash $334,659 $314,656 Accounts receivable 89,839 137,372 Accounts receivable, related party 24,663 29,195 Inventory 603,733 729,629 Inventory deposits 41,946 118,361 Prepaid and other current assets 178,193 126,857 Prepaid management fee - related party 3,500 -- Total current assets 1,276,533 1,456,070 Property and equipment, net 187,440 192,960 Other assets Intangible assets, net 207,064 212,149 Deferred debt issue costs 186,630 237,172 Deposits 176,324 177,661 Total other assets 570,018 626,982 Total assets $2,033,991 $2,276,012 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities Accounts payable $1,034,789 $769,184 Accrued interest, related party -- 114,792 Accrued interest, convertible notes 319,889 225,368 Accrued commissions 347,562 269,453 Accrued payroll and payroll tax 189,221 147,418 Accrued bonus 118,631 122,089 Deferred compensation 45,769 95,944 Deferred rent 52,844 51,435 Notes payable - related parties -- 339,159 Warrant derivative liability 2,078,690 219,489 Convertible notes payable, net 116,098 1,677,505 Total current liabilities 4,303,493 4,031,836 Long-term liabilities Minority interest in subsidiaries 55,497 52,279 Total liabilities 4,358,990 4,084,115 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock, 500,000,000 common shares, $0.001 par value, authorized, 157,285,122 and 111,707,051 shares issued and outstanding at March 31, 2006 and December 31, 2005, respectively 157,286 111,708 Additional paid in capital 7,893,181 6,529,428 Accumulated deficit (10,392,211) (8,461,960) Accumulated other comprehensive income 16,745 12,721 Total stockholders' equity (deficit) (2,324,999) (1,808,103) Total liabilities and stockholders' equity (deficit) $2,033,991 $2,276,012

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2006 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.